Joseph Jackson

One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United States

Background—Atherothrombosis is the underlying cause of cardiovascular, cerebrovascular, and peripheral arterial disease and is the leading cause of death in the industrialized world. The objectives of the present study are (1) to examine the annual costs associated with vascular events and interventions that require hospitalization, as well as long-term medication use for the management of associated risk factors, in a US population of outpatients with multiple atherothrombotic risk factors or a history of symptomatic disease and (2) to compare costs across patient subgroups defined according to specific arterial bed(s) affected and the number of affected arterial beds. Methods and Results—The international REduction of Atherothrombosis for Continued Health (REACH) Registry enrolled outpatients ≥45 years of age who had established coronary artery, cerebrovascular, or peripheral artery disease or ≥3 atherothrombotic risk factors. Data on risk factors, associated medications, and vascular hospitalizations and interventions were collected. Of the total 68 236-patient REACH cohort, 25 763 were enrolled from US sites. Complete 1-year data were available for 23 974 (93%) of the US patients. Annualized medication costs ranged from

Randomized, double‐blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair

2401 to

Multiple Co-primary Endpoints: Medical and Statistical Solutions: A Report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America

3481. Mean annual hospitalization costs per patient were

The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism *

1344,

Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial

2864,

Migraine therapy: development and testing of a patient preference questionnaire.

4824, and

The cardiovascular event reduction tool (CERT)—a simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS)

8155 for patients with 0 (n=6145), 1 (n=14 353), 2 (n=3106), and 3 (n=370) affected arterial beds at baseline (P<0.0001 for trend). Among patients with 1 affected arterial bed, mean hospitalization costs were

Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden

2999,

Long-term cost-effectiveness of clopidogrel in STEMI patients.

2010, and

Assessing Health State Utilities in Elderly Patients at Cardiovascular Risk

3911 for patients with coronary artery disease (n=11 063), cerebrovascular disease (n=2613), and peripheral arterial disease (n=677), respectively. Annualized medication costs ranged from